Last updated on April 2019

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL


Brief description of study

The purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029 in adult subjects with metastatic or locally advanced unresectable solid tumors or diffuse large B-cell lymphoma (DLBCL). PROCLAIM: PRObody CLinical Assessment In Man CX-2029 clinical trial 001

PROBODY is a trademark of CytomX Therapeutics, Inc

Clinical Study Identifier: NCT03543813

Find a site near you

Start Over

University of Southern California

Los Angeles, CA United States
  Connect »

Yale Cancer Center

New Haven, CT United States
  Connect »

START Midwest

Grand Rapids, MI United States
  Connect »

MD Anderson Cancer Center

Houston, TX United States
  Connect »

Virginia Cancer Specialists

Fairfax, VA United States
  Connect »